Deslorelin

Overview

Deslorelin (Suprelorin®) is a GnRH superagonist used in dogs and cats to induce temporary chemical castration. It is available as a long-acting subcutaneous implant that provides reversible suppression of reproductive function.

Following implantation, there is an initial stimulation phase during the first 1–2 weeks, after which prolonged receptor overstimulation leads to suppression of gonadotropin release. This results in decreased testosterone production and inhibition of spermatogenesis.

Mechanism of Action (MOA): Deslorelin initially stimulates GnRH receptors, causing a transient increase in LH and FSH release. With continued exposure, these receptors become desensitized and downregulated, leading to suppression of LH and FSH secretion and subsequent reduction in testicular function.

Indications

Deslorelin is used in dogs and cats primarily for reversible suppression of reproductive function. It provides a non-surgical alternative to castration through temporary hormonal suppression.

• Temporary chemical castration: Used in male dogs and cats to suppress testosterone production and spermatogenesis.
• Fertility control: Provides reversible infertility, typically beginning about 6 weeks after implantation.
• Long-term suppression: Duration depends on implant type, providing approximately 6 or 12 months of effect in dogs and longer durations in cats.
• Alternative to surgical castration: Suitable for owners seeking temporary or reversible reproductive suppression.

Dosage (Reference)

Dog

In dogs, deslorelin is administered as a subcutaneous implant for temporary chemical castration. The effect depends on the implant strength and is reversible over time.

Cat

In male cats, deslorelin is administered as a subcutaneous implant to induce long-term reversible suppression of reproductive function.

Warnings & Precautions

Deslorelin implants should be used with appropriate handling and implantation technique to ensure efficacy and minimize complications. Careful consideration is required in specific patient populations.

• Hypersensitivity: Contraindicated in animals with known hypersensitivity to deslorelin acetate.
• Administration technique: Implant subcutaneously in loose skin (between lower neck and lumbar area); avoid placement in fat as this may impair drug release.
• IV administration: Do not administer injectable formulations intravenously.
• Initial stimulation phase: A transient increase in reproductive hormones may occur during the first 1–2 weeks before suppression develops.
• Implant removal: Implants are biocompatible and do not require removal, but can be surgically removed under local anesthesia if early termination of effect is needed.
• Handling precautions: Avoid direct skin contact, particularly in pregnant women or women of childbearing age; use appropriate protective measures.
• Infection prevention: Proper disinfection of the implantation site is required to reduce risk of infection.
• Pregnancy and reproduction: Use only if benefits outweigh risks; safety in breeding animals is not fully established.

Drug Interactions

No clinically significant drug interactions have been specifically reported with deslorelin in dogs and cats. However, general caution is advised when combining with other hormonal or reproductive-modulating therapies.

• No specific interactions identified: Current data do not indicate significant drug–drug interactions in veterinary patients.

Side Effects & Overdose

Side Effects

Adverse effects of deslorelin in dogs and cats are generally mild and related to local reactions or hormonal changes associated with its mechanism of action.

• Injection/implant site reactions: Mild swelling, sensitivity, or increased local temperature may occur and typically resolves within a few days.
• Initial hormonal flare: Temporary increase in reproductive hormones during the first 1–2 weeks may occur before suppression develops.
• Prolonged reproductive suppression: In some cases, recovery of normal reproductive function may be delayed after treatment.
• Reproductive effects (female dogs, extra-label use): Rarely associated with prolonged estrus, follicular cysts, or pyometra.

Overdose

Limited information is available regarding overdose in dogs and cats. Clinical effects are generally related to exaggerated pharmacologic activity.

• Systemic reactions: High doses may cause signs such as tremors, hives, or increased heart and respiratory rates.
• Multiple implants: Accidental additional implantation may prolong duration of effect; implants can be removed if detected early.
• Management: Supportive care is recommended; no specific antidote is available.

Key Notes

Practical clinical insights to guide effective and predictable use of deslorelin in dogs and cats:

• Reversible fertility control: Effects are temporary, allowing return of reproductive function after the implant’s activity declines.
• Predictable duration: Duration of action is linked to implant size (short vs long acting), aiding in treatment planning.
• Breed and size variability: Smaller dogs may experience longer duration of suppression compared to larger dogs.
• Non-surgical option: Useful alternative when anesthesia or surgery is not desired or contraindicated.
• Implant location matters: Proper placement in well-vascularized subcutaneous tissue is essential for consistent drug release.
• Long-term planning: Regular re-implantation schedules are needed to maintain continuous reproductive suppression.